Leadership Changes at DBV Technologies
DBV Technologies, a prominent clinical-stage biopharmaceutical company, has announced an exciting addition to its Board of Directors. The company has recently appointed Dr. Philina Lee as an independent director, replacing Daniel Soland. This provisional appointment is subject to ratification by shareholders at the next annual meeting. With this change, the board will now consist of ten members.
Philina Lee's Expertise
Dr. Philina Lee comes to DBV Technologies with an impressive background in the biopharmaceutical sector. She has demonstrated her leadership capabilities at Blueprint Medicines, where she rose through the ranks to become the Chief Commercial Officer. In this role, she was instrumental in launching and growing the drug AYVAKIT®. Moreover, she has served on the Board of Directors for Fusion Pharmaceuticals, contributing to vital committees that influence the strategic direction of the company.
Company's Commitment to Allergy Treatment
Dr. Lee expressed her excitement over joining the board during a crucial phase for DBV Technologies, especially as they advance their innovative treatment VIASKIN® Peanut, targeting children and toddlers affected by peanut allergies. She stated her intent to contribute significantly to the company’s growth and the successful outcomes of its projects.
About DBV Technologies
DBV Technologies is dedicated to creating groundbreaking treatments for food allergies and other immunological conditions, addressing significant unmet medical needs. The company is particularly focused on its proprietary VIASKIN® patch technology, designed to treat food allergies through epicutaneous immunotherapy (EPIT). This innovative approach allows microgram quantities of biologically active compounds to penetrate the immune system via the skin, promoting a desensitization effect by retraining the immune response.
Current Clinical Trials
The company is currently conducting clinical trials using the VIASKIN® patch for toddlers aged 1 to 3 years and children aged 4 to 7 years who suffer from peanut allergies. This reflects DBV Technologies’ commitment to transforming the lives of individuals affected by food allergies, particularly among the pediatric population.
Headquarters and Operations
DBV Technologies operates globally, with its headquarters in France and additional operations based in Warren, New Jersey. The company’s ordinary shares are listed on segment B of Euronext Paris under the ticker DBV, while its American Depository Shares are traded on the Nasdaq Capital Market under the ticker DBVT.
Investor Relations
For inquiries, investors can reach out to Katie Matthews via email at katie.matthews@dbv-technologies.com. Additionally, media inquiries should be directed to Brett Whelan at brett.whelan@dbv-technologies.com. DBV Technologies remains dedicated to keeping stakeholders informed as it evolves and progresses in the development of its innovative therapies.
Frequently Asked Questions
What recent changes has DBV Technologies made to its board?
DBV Technologies has appointed Dr. Philina Lee as an independent director to its Board, replacing Daniel Soland.
What is Dr. Philina Lee's background?
Dr. Lee has significant experience in the biopharmaceutical industry, previously serving as Chief Commercial Officer at Blueprint Medicines.
What is VIASKIN®?
VIASKIN® is a patch technology developed by DBV Technologies, aimed at treating food allergies through a non-invasive epicutaneous immunotherapy method.
Who can benefit from DBV's treatments?
DBV Technologies focuses on treating children and toddlers who suffer from food allergies, particularly peanut allergies.
How can investors contact DBV Technologies?
Investors can contact DBV Technologies’ investor relations team through Katie Matthews at her provided email address.
